Security Snapshot

Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) Institutional Ownership

CUSIP: 03843E104

13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

177

Shares (Excl. Options)

71,672,682

Price

$4.15

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.001 par value
Symbol
AQST on Nasdaq
Shares outstanding
120,192,308
Price per share
$4.05
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
71,672,682
Total reported value
$297,443,720
% of total 13F portfolios
0%
Share change
+7,541
Value change
-$19,848,458
Number of holders
177
Price from insider filings
$4.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 03843E104.
  • 177 institutions reported positions in Q1 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 178 to 177 between Q4 2025 and Q1 2026.
  • Reported value moved from $466,378,990 to $297,443,720.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 177 institutions filings for Q1 2026.

Open SEC Evidence

Security key

03843E104

Latest holder period

Q1 2026

13F holders

177

13D/G owners

4

CIK / CUSIP context first

Open Q1 2026 holders AQST full holder history Aquestive Therapeutics, Inc. SEC filings Aquestive Therapeutics, Inc. company facts Aquestive Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRATTON DOUGLAS K 11% $28,720,687 10,077,434 BRATTON DOUGLAS K 31 Dec 2024
BlackRock, Inc. 5.3% $35,923,900 6,426,343 BlackRock, Inc. 30 Sep 2025
RTW INVESTMENTS, LP 5.2% $34,937,500 6,250,000 RTW Investments, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% $7,494,890 2,629,786 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024

As of 31 Mar 2026, 177 institutional investors reported holding 71,672,682 shares of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST). This represents 60% of the company’s total 120,192,308 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bratton Capital Management, L.P. 8.2% 9,810,958 0% 100% $40,715,476
BlackRock, Inc. 6.2% 7,509,071 -3.4% 0% $31,162,644
RTW INVESTMENTS, LP 6.2% 7,426,471 +19% 0.31% $30,819,855
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 4,443,698 0% 0% $18,441,347
FEDERATED HERMES, INC. 2.4% 2,940,339 +45% 0.02% $12,202,407
Balyasny Asset Management L.P. 2.4% 2,900,570 +199% 0.02% $12,037,366
STATE STREET CORP 2.1% 2,546,191 +3.4% 0% $10,566,693
SAMSARA BIOCAPITAL, LLC 2.1% 2,500,000 0% 1% $10,375,000
GEODE CAPITAL MANAGEMENT, LLC 2% 2,408,191 +1.7% 0% $9,996,351
BANK OF AMERICA CORP /DE/ 2% 2,405,050 +99% 0% $9,980,958
Sio Capital Management, LLC 1.6% 1,922,887 +94% 1.2% $7,979,981
MORGAN STANLEY 1.3% 1,591,792 -9.5% 0% $6,605,938
Blue Owl Capital Holdings LP 1.1% 1,347,932 +157% 1.5% $5,593,918
TWO SIGMA INVESTMENTS, LP 0.95% 1,139,404 +199% 0% $4,728,527
Janney Montgomery Scott LLC 0.91% 1,089,110 -0.38% 0.01% $4,520,000
COMMONWEALTH EQUITY SERVICES, LLC 0.9% 1,082,680 +6.2% 0.01% $4,493,124
WELLS FARGO & COMPANY/MN 0.86% 1,034,644 -13% 0% $4,293,773
JANE STREET GROUP, LLC 0.86% 1,030,050 +101% 0% $4,274,707
WASATCH ADVISORS LP 0.73% 878,316 +29% 0.02% $3,645,011
BNP PARIBAS FINANCIAL MARKETS 0.67% 809,007 0% 0% $3,357,379
BARCLAYS PLC 0.66% 799,163 +134% 0% $3,316,526
NORTHERN TRUST CORP 0.61% 732,504 -1.4% 0% $3,039,892
Propel Bio Management, LLC 0.59% 710,988 1.9% $2,950,600
VANGUARD PORTFOLIO MANAGEMENT LLC 0.58% 691,750 0% 0% $2,870,763
VANGUARD FIDUCIARY TRUST CO 0.53% 637,512 0% 0% $2,645,675

Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 71,672,682 $297,443,720 -$19,848,458 $4.15 177
2025 Q4 72,216,999 $466,378,990 +$34,098,128 $6.46 178
2025 Q3 66,072,635 $369,385,999 +$106,443,073 $5.59 151
2025 Q2 47,601,655 $157,593,347 +$12,692,456 $3.31 115
2025 Q1 44,051,858 $127,751,552 -$2,587,459 $2.90 120
2024 Q4 43,378,481 $154,428,036 -$13,648,629 $3.56 113
2024 Q3 46,754,842 $232,438,651 +$19,226,897 $4.98 116
2024 Q2 42,397,820 $110,236,742 -$9,111,350 $2.60 95
2024 Q1 41,491,141 $176,751,489 +$88,086,384 $4.26 96
2023 Q4 23,788,793 $48,053,747 +$1,931,780 $2.02 57
2023 Q3 13,082,950 $20,018,501 +$5,799,587 $1.53 45
2023 Q2 19,076,504 $31,486,971 +$6,895,297 $1.65 54
2023 Q1 14,936,175 $17,026,675 +$181,515 $1.14 34
2022 Q4 14,914,775 $13,452,963 -$924,306 $0.90 34
2022 Q3 15,885,912 $18,581,000 -$701,258 $1.17 41
2022 Q2 16,697,754 $10,681,727 -$1,110,269 $0.64 37
2022 Q1 15,540,728 $40,562,854 -$1,905,712 $2.61 49
2021 Q4 16,159,821 $62,860,046 +$1,542,125 $3.89 50
2021 Q3 14,777,244 $64,430,510 -$3,394,828 $4.36 44
2021 Q2 15,624,060 $62,031,877 -$6,395,474 $3.97 56
2021 Q1 16,607,064 $86,353,974 -$13,347,120 $5.20 62
2020 Q4 19,140,719 $102,400,992 -$3,894,598 $5.35 65
2020 Q3 19,883,853 $96,529,634 +$6,732,727 $4.85 57
2020 Q2 18,511,676 $89,959,616 +$16,355,927 $4.86 56
2020 Q1 15,971,551 $35,033,099 -$11,294,638 $2.19 42
2019 Q4 17,453,204 $101,100,262 +$20,834,844 $5.82 55
2019 Q3 13,582,404 $43,193,449 -$3,717,359 $3.18 34
2019 Q2 14,515,951 $60,964,876 -$1,002,690 $4.20 39
2019 Q1 14,418,719 $99,632,199 +$442,125 $6.91 49
2018 Q4 14,369,495 $90,526,000 -$232,037,542 $6.30 35
2018 Q3 16,085,145 $281,645,000 +$281,645,001 $17.51 44
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .